KRAS and colorectal cancer: We also evaluated the potential for the simultaneous use of 89Zr-matuzumab PET/CT and nimotuzumab-PEG6-DM1 for biparatopic imaging and therapy, respectively, in EGFR-positive KRAS mutant colorectal cancer models.